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Summary Inhibitory concentrations (ICs) against human bone marrow granulocyte-macrophage colony
forming cells (GM-CFC) were established for 26 cancer chemotherapy agents, including seven investigational
agents by ten day exposure. Each drug was tested at four or more concentrations to generate reliable survival
curves. The analysis of the survival curves produced three patterns according to which drugs were classified:
class A drugs had a shouldered curve with terminal exponential kill of GM-CFC, class B drugs produced
initial exponential component followed by a plateau, and class C drugs produced linear curves. These
categories provide the relationship between drug concentration and cytotoxicity, e.g., the cytotoxicity of class
B drugs, after initial kill, did not increase in spite of serial doubling of concentrations whereas the class C
drugs had proportional killing with two-fold concentration increments. A number of drugs were active at in
vitro concentrations of .0.01plgml-1 and caused log reduction of GM-CFC with an approximate
concentration of 0.001 ygml-1. Drugs known to require in vivo bioactivation, namely dacarbazine,
procarbazine, and ifosfamide were active at high concentrations (>1lO.Opgm1 1). We propose that for
myelosuppressive agents the GM-CFC provides a useful biologic reference to determine in vitro cut off
concentrations to be utilized for drug screening. For nonmyelosuppressive agents, however, it may be
suboptimal.
The human tumour cloning assay has been investi-
gated for screening of the new chemotherapeutic
agents. If such a method becomes successful in
identifying potential clinically active agents, a
number of laborious and expensive phase II trails
could be reduced, moreover, some agents may be
prevented from entering phase I trials. However, in
using a human tumour stem cell assay (HTSCA) to
predict clinical response and screening of new
agents, one of the major considerations has been
the dilemma of defining appropriate in vitro con-
centrations of the cytotoxic agents, since inappro-
priately high or low concentrations may produce
erroneous conclusions. Von Hoff et al. (1981) and
Alberts et al. (1981) in their attempts to screen new
agents, have exposed tumour cells to a concentra-
tion corresponding to one tenth of the peak plasma
levels derived from clinical pharmacologic studies.
Tumour cells were routinely exposed for one hour.
This approach may have validity for those drugs
with well established human pharmacology.
The problem is compounded further in screening
of the investigational agents due to minimum or no
human pharmacology data. Therefore, the selection
of an in vitro concentration of chemotherapy agents
has been arbitrary. For the purpose of new drug
screening, not uncommonly, the in vitro concentra-
tions vary from a routine use of 10Mgml-I exposed
continuously for the duration of culture to a range
of concentrations over several logs e.g., 0.1, 1.0,
2.5, and 10.0/4ugml-l as continuous or 1 h
exposure. The drugs are pursued further if the in
vitro antitumour activity is present at lower two
concentrations (Jiang et al., 1983a,b; Rozencweig et
al., 1984, 1985; Salmon et al., 1981a,b; Shoemaker
et al., 1984, 1985). The relationship between a given
concentration, e.g., l0 g ml-1, of one drug to that
of another drug is completely unknown and can
not be defined because the biologic activity of two
drugs against human tumours may be quite
different at the same concentration. In stead one
would prefer to compare antitumour activity of
different drugs at similar biologic reference points
that correspond to various drug concentrations.
A system that would grade concentrations of
various drugs to one or more predetermined
biologic reference(s) is possible by utilization of a
'biologic control'. A biologic control that provides
various reference points for drugs may help select
appropriate in vitro concentrations and minimize
errors in prediction of activity or inactivity. A
biologic control may provide insights into a need
for in vitro drug bioactivation, drug stability, and
would define survival curves. Previously we
reported that the breast tumours that ,were more
sensitive in vitro than were GM-CFC to myelo-
suppressive cytotoxic agents, usually responded in
vivo to the same agents (Hug et al., 1984). We,
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therefore, examined the utility of human bone
marrow granulocyte-macrophage colony forming
cells in culture as a biologic reference. It is
acknowledged that GM-CFC as a biologic
reference would be logical for clinically myelosup-
pressive agents but less ideal for marrow sparing
drugs. However, the myelosuppressive agents do
form a majority in the currently available drug
armamentarium.
We choose continuous drug exposure over short
exposures since the continuous exposure does not
significantly alter the activity of cell cycle non-
specific agents and yet it is most appropriate for
cell cycle specific drugs (Ludwig et al., 1984). There
has been an increase in the use of prolonged
infusion of cell cycle specific drugs. Clinical correla-
tions have been obtained by utilizing continuous in
vitro drug exposure (Ajani et al.,. 1986).
These considerations lead us to conclude that the
in vitro monitoring of drug activity on normal
tissues or malignant cell lines, which exhibit less
variability than heterogeneous primary tumours
could be of value in: a) understanding the drug
concentrations needed to test clinically active drugs,
b) defining the in vitro biologic activity of investi-
gational agents before screening against human
tumours, and c) achieving a ranking system which
provides perspective for all drugs. We report in
vitro activity of 26 chemotherapy drugs, including
a number of investigational agents, exposed con-
tinuously at various concentrations against the
GM-CFC.
Materials and methods
Cell collection and separation
Bone marrow cells were obtained by aspiration of
posterior iliac crest from normal allogeneic donors
and from cancer patients with marrow free of
tumour infiltration. Aspirates were added to tubes
containing 1 ml PBS and 300 units of preservative-
freeheparin(FisherScientific,Houston,Texas).Mono-
nuclear cells were separated by Ficoll-Hypaque
(Sigma Chemical Company, St. Louis, Missouri)
density-gradient centrifugation (d= 1.077gml 1).
Drug preparation
All drugs (with the exception of retinoic acid) were
diluted with 0.9% NaCl or distilled water, stored in
0.1 ml aliquots at -70°C, and used within one
month.
Retinoic acid was dissolved in 95% ethanol at a
concentration of 5mM and stored in the dark at
-20°C. Dilutions for addition to the culture system
were made in the culture medium containing foetal
bovine serum, stored at 4°C, and used within one
week. Subdued light conditions were implemented
for all retinoic acid work (Findley et al., 1984).
The following commerciafly available drugs were
used: dactinomycin (Merck, Sharp and Dohme,
West Point, Pennsylvania), bleomycin sulfate,
carmustine, cisplatin, etoposide, mitomycin-C
(Bristol Laboratories, Syracuse, New York), cytara-
bine (Upjohn, Kalamazoo, Michigan), dacarbazine
(Miles Pharmaceuticals, West Haven, Connecticut),
doxorubicin HCI, 5-fluorouracil (Adria Labora-
tories, Milan, Italy), all trans retinoic acid (Sigma
Chemical Company, St. Louis, Missouri), and
vinblastine sulfate and vincristine sulfate (Eli Lilly
and Company, Indianapolis, Indiana).
The following investigational drugs were
obtained from the National Cancer Institute, Silver
Springs, Maryland: caracemide, platinum dichloro-
dihydroxybis-(2-propamine)-(OC-6-33) (CHIP), 4-
dimethoxydaunorubicin (DMDR), dihydro-5-
azacytidine HCI, fludarabine phosphate, ifosfamide,
melphalan (i.v. formulation), mitoxantrone HCI,
taxol, tiazofurin and nafidimide.
All drug concentrations listed in the experiments
are based on the total volume of the agar-medium
mixture in the culture dish.
Bone marrow culture
A modified bilayer soft agar system was used for
colony formation of GM-CFC (Verma et al., 1980).
The 1 ml underlayer consisted of 0.4ml of 2X alpha
minimal essential medium plus 30% foetal bovine
serum (MEM; K. C. Biological), 0.2ml of human
placenta conditioned medium, and 0.4ml of 1.25%
Bacto-Agar (Difco, Detroit, Michigan). All cultures
were done in 35-mm plastic petri dishes (Corning
Glass Works, Corning, New York).
After solidification, the underlayers were overlaid
with a 1 ml mixture containing 0.025ml of graded
drug concentrations (0.9% NaCl or distilled water
in control plates), 0.4ml of 2X alpha MEM plus
30% foetal bovine serum, 0.5ml of 0.75% agar,
and 200,000 bone marrow cells in IX alpha MEM
plus 15% foetal bovine serum. In all experiments,
triplicate cultures were run for each drug concentra-
tion. The cultures were incubated for 8 to 10 days
in a humidified atmosphere of 5% C02, 12% 02'
and balanced N2 at 37°C. The GM-CFC (aggre-
gates of 40 or more cells) were scored with an
Olympus stereoscopic zoom microscope (Olympus
Corporation, New Hyde Park, New York) at 30 x
magnification. Only cultures with 30 colonies or
more (cloning efficiency of 0.02%) were used in the
evaluation of drug cytotoxicity. The mean cloning
efficiency was 0.06%, with a range of 0.02% to
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Statistical analysis
Each drug was tested on cells from five different
bone marrows. Survival fractions of GM-CFC were
calculated as the mean number of colonies in the
experimental dishes divided by the mean number of
colonies in the control dishes multiplied by 100.
Mean and standard deviation were calculated for
each drug concentration based on the results of the
5 tests, and the 'best fit' curve was drawn on a
semilog scale.
Results
All 26 chemotherapeutic agents were tested against
GM-CFC at at least four different concentrations
to generate survival curves. For each drug a pilot
experience determined a concentration resulting in
some inhibition of GM-CFC. Subsequent con-
centrations were derived by doubling of the
previous one thus resulting in a range of four or
more concentrations and yet within a narrow
spectrum usually within one log. The highest con-
centration was up to 4 fold higher than the GM-
CFC IC 99. The concentrations resulting in the
targeted GM-CFC inhibition were extrapolated
from the survival curves. The definition of the
targeted GM-CFC inhibitory concentrations (IC),
e.g., IC 40, IC 50, IC 78, and IC 90-99, for each
drug was considered essential to establish uniform
biologic reference points with which all agents
could be compared. These values were derived also
for the seven investigational agents caracemide,
dihydro-5-azacytidine, 4- dimethoxydaunorubicin,
ifosfamide, nafidimide, taxol, and tiazofurin.
Based on the shapes of the survival curves
generated for 26 drugs, we divided drugs in three
main categories: a) Class A drugs - drugs which
had initial shoulders on their survival curves but
with increasing concentration the curve became
steep, b) Class B drugs - drugs which had
exponential killing of GM-CFC with initial con-
centrations but inspite of increasing concentration a
plateau was reached, and c) Class C drugs - drugs
that demonstrated linear inhibition of the GM-
CFC.
Sixteen of 26 (62%) could be classified as Class
A drugs producing an initial shoulder. The
standard agents in class A category included:
dactinomycin, mitoxantrone, vincristine,
dacarbazine, 5-fluorouracil, melphalan, and
etoposide, and the investigational agents in class A
category included: DMDR, taxol, CHIP, ifosfa-
mide, dihydro-5-azacytidine, fludarabine phosphate,
nafidimide, spirogermanium, and tiazofurin. The
extrapolated GM-CFC IC 40, 50, 78, and 90 to 99
for some of the class A drugs are listed in Table I;
these values on the remaining drugs have been
published (Umbach et al. 1984a,b; 1985). The parts
A and B of Figure 1 depict the survival curves of
the representative class A agents e.g., dactinomycin,
DMDR, mitoxantrone, taxol, and vincristine. All
five drugs achieved GM-CFC IC 99 at a concentra-
tion of <0.0025ygml-1.
Four drugs which had GM-CFC survival curves
without shoulders but achieved a terminal plateau
phase indicating substantial decrease in activity in
spite of doubling of the drug concentration. These
agents in group B were bleomycin, cytarabine,
caracemide, and retinoic acid. The GM-CFC IC 40,
50, 78 and 90 to 98 for these drugs are shown in
Table II.
The remaining six drugs constituted group C and
had a linear GM-CFC survival curve; meaning a
proportionate decrease in the bone marrow cell
survival with doubling of the concentration. The
drugs in this group included vinblastine,
procarbazine (procarbazine being active at con-
centration above 10/4ugml-1), mitomycin-C, cis-
platinum, carmustine and doxorubicin. GM-CFC
IC 40, 50, 78 and 90 to 98 for these agents are
shown in Table III.
Figure 2 depicts the GM-CFC survival curves
generated by dacarbazine, procarbazine, and
ifosfamide, all of which require in vivo activation
for optimal cytotoxic activity. In contrast to the
drugs represented in Figure 1, ifosfamide,
procarbazine, and dacarbazine resulted in GM-CFC
IC 90 at concentration in excess of 10jigml 1.
Discussion
It is difficult to mimic in vivo milieu for in vitro
drug testing. It is difficult also to extrapolate con-
centration and half life of drugs in the tumour bed
with the knowledge of serum concentrations
achieved by various dosage and infusion schedules.
However, an accurate in vitro concentration range
would be ideal to avoid erroneous results. A bio-
logic reference in this regard can be utilized to
define appropriate in vitro concentrations, especially
for drugs with unknown human pharmacology.
We used GM-CFC as an in vitro biologic refer-
ence to define drug concentrations in our assay.
The analysis of the survival curves allowed us to
classify and understand the dose-response relation-
ship of these drugs. GM-CFC assay may be
appropriate for drugs which cause significant
myelosuppression clinically. At higher in vitro con-
centrations, the drugs which cause mild or no
myelosuppression at maximally tolerated doses,
result in inhibition of GM-CFC. Thus the GM-IN VITRO TOXICITY ON HUMAN GM-CFC
Table I Group A drugs: In vitro drug concentration (ggml-1) for
granulocyte-macrophage colony-forming cells.
% Inhibitory concentration
Group A drugs 40 50 78 90-98
CHIP 0.5 0.6 1.2 2.5
Dacarbazine 60.7 71.4 114.0 250.0
Dactinomycin 0.0005 0.0006 0.00096 0.00123
4-Demethoxydaunorubicin 0.0005 0.0007 0.0016 0.0025
Dihydro-5-azacytidine HCI 4.4 5.3 7.4 10.0
Etoposide 0.038 0.045 0.070 0.11
Ifosfamide 19.9 25.1 48.9 90.0
Mitoxantrone HCI 0.0006 0.00008 0.00014 0.00025
Nafidimide 0.083 0.094 0.13 0.2
Taxol 0.0036 0.0040 0.0048 0.005
Tiazofurin 0.45 0.61 1.27 2.5
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Figure 1 Granulocyte-macrophage colony-forming cell
survival curves for five group A drugs active at
concentrations <0.01 jgml-'. (a) actinomycin (0);
dimethoxydaunorubicin (0); vincristine (A); (b) taxol
(L.H. panel) and mitoxantrone (R.H. panel).
CFC assay overestimates their concentrations.
Eighteen of 26 drugs achieved GM-CFC IC 99 at
concentration <1jIgml-1. Only four drugs, carace-
mide, dihydro-5-azacytidine, retinoic acid, and
carmustine, which do not require bioactivation in
vitro, were inactive at concentration <1jIgml- 1.
This could be contrasted with the concentrations
utilized for screening new drugs (Shoemaker et al.,
1984; 1985).
We have recently described a human tumour cell
assay that uses a tumour matrix for the growth of
tumour cells (Ajani et al., 1985; Baker et al., 1986).
With in vitro sensitivity of human tumours to
cytotoxic agents defined as .50% inhibition of
growth, clinically known active agents, e.g., cispla-
tinum, doxorubicin, 5-fluorouracil, etoposide,
mitomycin, and vinblastine had a response rate of
30% or greater when the drugs were tested at
concentrations up to GM-CFC IC 90.
Shoemaker et al. (1985), for screening of new
drugs, have tested a number of agents including
actinomycin, spirogermanium, dihydroxyanthra-
cenedione, bleomycin, cisplatinum, 1-Beta-D-
arabino furanosylcytosine, vinblastine, carmustine,
5-fluorouracil, vincristine sulphate, taxol,
melphalan, procarbazine, and dacarbazine. Procar-
bazine and dacarbazine were inactive as they
resulted in the lowest in vitro response rate.
However, the myelosuppressive agents such as
actinomycin and dihydroxyanthracenedione, two of
the three (along with spirogermanium) were the
most active drugs but were tested at concentrations
5 to 6 logs higher than GM-CFC IC 50. Spiro-
germanium was tested at a concentration two logs
higher than its GM-CFC IC 50; spirogermanium's
dose-limiting toxicity is not myelosuppression but it
is neurological, thus, the concentration correspon-
ding to _GM-CFC IC 50 would be biologically
very high. Bleomycin was active also with an in
610 J.A. AJANI et al.
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Table II Group B drugs: In vitro drug concentrations (pgml -1) for
granulocyte-macrophage colony-forming cells
% Inhibitory concentration
Group B drugs 40 50 78 90-98
Bleomycin sulfate 0.36 0.51 1.37 4.0
Caracemide 0.57 0.93 4.72 10.0
Cytarabine 0.0013 0.0016 0.0025 0.0063
Retinoic acid 2.7 3.9 9.9 19.2
Table III Group C drugs: In vitro drug concentrations (pgml-1) for
granulocyte-macrophage colony-forming cells.
% Inhibitory concentration
Group C drugs 40 50 78 90-98
Carmustine 1.11 1.43 2.6 5.0
Doxorubicin HC1 0.0017 0.0023 0.005 0.01
Vinblastine 0.0003 0.0004 0.0010 0.0025
Cisplatinum 0.23 0.36 0.73 1.0
Mitomycin-C 0.0032 0.0044 0.010 0.025
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Figure 2 Granulocyte-macrophage colony-forming cell
survival curves for three drugs known to require in
vivo bioactivation. Dacarbazine (0); procarbazine
(0); ifosfamide (/\).
vitro response rate of 33%, however, bleomycin is
also nonmyelosuppressive clinically. This is a
limitation of the GM-CFC assay. The appropriate
in vitro concentrations for the mildly myelosuppres-
sive or nonmyelosuppressive agents could be
determined accurately by sensitive human tumour
cell lines.
-The study by Shoemaker et al. (1985) suggests
that the in vitro activity of clinically known myelo-
suppressive agents was proportional to the con-
centration number of logs above the GM-CFC IC
50 (see their Tables 4 and 5). Drugs tested at
concentrations closer to GM-CFC IC 50 included
cisplatinum, 5-fluorouracil, carmustine, and
melphalan resulted in in vitro responses consistent
with the clinical experience. Vincristine and cytara-
bine which were both tested at approximately 4
logs above GM-CFC IC 50 had higher in vitro
activity.
Salmon et al. (1984) compared cytotoxic effects
of esorubicin with doxorubicin against human
tumour samples and normal bone marrow cells and
concluded that esorubicin might be more effective
and less toxic than doxorubicin. The median _612 J.A. AJANI et al.
Table IV Comparison of in vitro tumor responses and inhibitory
concentration (IC-50) for granulocyte-macrophage colony-forming cells
(GM-CFC).
JOpg-.
% in vitroa GM-CFC GM-CFC
Drug response IC 50 (*gml-1) IC 50
Actinomycin 47 0.00062 1.6 x 104
Spirogermanium 41 0.14 0.7 x 102
Mitoxantrone 40 0.00008 1.3 x 105
Bleomycin 33 0.51 2.0 x 10'
Cisplatinum 24 0.27 3.7 x 101
Cytarabine 22 0.0016 6.25 x 103
Vinblastine 21 0.0004 2.5 x 104
Carmustine 21 1.43 7.0
5-Fluorouracil 21 0.47 2.1 x 101
Vincristine 20 0.0010 1.0 x 104
Taxol 10 0.004 2.5 x 103
Melphalan 10 0.22 4.5 x 101
Procarbazine 8 60.9 0.16
Decarbazine 8 70.42 0.14
aFrom Shoemaker et al. (1985).
Table V Comparison of in vitro tumour responses and inhibitory
concentration (IC-50) for granulocyte-macrophage colony-forming cells
(GM-CFC).
JOpg-.
% in vitroa GM-CFC GM-CFC
Drugs response IC 50 (ugml 1) IC 50
Actinomycin 70 0.00062 1.6 x 104
Mitomycin 69 0.0044 2.3 x 103
Doxorubicin 65 0.0023 4.3 x 103
Cisplatinum 54 0.27 3.7 x 101
Bleomycin 32 0.51 2.0x 101
Vinblastine 31 0.0004 2.5 x 104
Carmustine 23 1.43 7.0
5-Fluorouracil 23 0.47 2.1 x 101
Melphalan 21 0.22 4.5 x 101
aFrom Shoemaker et al. (1985), (after establishment of 4 quality
controls).
tumour colony IC 50 value for esorubicin was the GM-CFC IC range to determine its activity
0.154ugml-l and for doxorubicin was 1.6ygml-', against fresh human tumours. We recommend
however, the median bone marrow colony IC 50 for utility of the malignant cell lines from relatively
esorubicin was 0.002 gml-P only and for doxoru- sensitive tumours as biologic control for clinically
bicin was 0.2ygml-1. If one were to utilize the nonmyelosuppressive agents.
GM-CFC assay as a biologic reference then a very We conclude that a) the chemotherapeutic agents
low concentration (neary two logs lower than can be divided into three classes e.g., group A with
doxorubicin) of esorubicin would be biologically initial shoulder, group B with terminal plateau, and
equal to a concentration of doxorubicin and it group C with lineal killing. Such grouping helps in
could be concluded that esorubicin is not superior the understanding of dose-dependent cytotoxicity
to doxorubicin. by various agents and provides an insight in their
To screen a new agent, it would be useful to first cytotoxic mechanism of action; b) GM-CFC IC 50
establish a GM-CFC survival curve then to include for a majority of the drugs is considerably less thanIN VITRO TOXICITY ON HUMAN GM-CFC 613
10pgml-1, the range usually selected for screening
investigational agents (Shoemaker et al., 1984;
1985), and c) investigational agents showed marked
differences in the GM-CFC IC 50 suggesting that
arbitrarily chosen concentrations may not give
accurate results.
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